Remission of alopecia universalis in a patient with atopic dermatitis treated with dupilumab

Alopecia areata (AA) is known to be associated with atopic dermatitis (AD).1,2 Based on retrospective studies and meta-analyses, patients with AD have higher rates of AA, and the inverse has also been found.1-4 The comorbidity of AA with AD is potentially related to their common immunologic pathways involving the helper T cell (Th), type 2 (Th2) immune response.1-5 Dupilumab, a fully monoclonal antibody against interleukin (IL)-4 receptor α, downregulates the Th2 pathway through inhibition of IL-4 and IL-13 and was approved for the treatment of refractory moderate to severe atopic dermatitis in March 2017 by the US Food and Drug Administration.